The meeting is part of our successful Drug Discovery series which includes innovative meetings on the Human Microbiome, Synthetic Biology, qPCR / dPCR, Digital Pathology & Biologics among others.
Recent advancements in the biomarker, CDx genomic and big data space have meant that some of the fundamental challenges of precision medicine are being realised. The potential for personalized medicine and therefore the possibility of delivering superior outcomes for patients is in reach. There is, however, a lot more to do. Alongside the continued developments in science as well as improvements in clinical trial design, support mechanisms such as market access /reimbursement/ regulatory strategies need to be further developed. Continued work by all stakeholders is therefore vital for success.
The congress was designed for a variety of stakeholders from drug and DX developers, payers, healthcare providers, academics to technology solution providers and will bring together a community of experts working in all areas of precision and personalised medicine such as biomarkers, CDx, translational medicine, clinical trials, genomics, NGS, bioinformatics and health economics.
The meeting provides the opportunity to take home cutting edge strategies, case study examples and methods to allow you to both implement and take the vital next steps in delivering precision medicine.